Biguanides. Mode of action and role in the up-to-date treatment of diabetes mellitus.
D000138:Acidosis / Q000139:chemically induced; D000284:Administration, Oral; D001645:Biguanides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications; D007773:Lactates / Q000097:blood; D010629:Phenformin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use
D001645:Biguanides; D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D007328:Insulin; D007773:Lactates; D013453:Sulfonylurea Compounds; D010629:Phenformin